Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
15.08
-0.11 (-0.72%)
NASDAQ · Last Trade: Mar 27th, 6:56 PM EDT
Detailed Quote
Previous Close
15.19
Open
15.09
Bid
14.83
Ask
15.11
Day's Range
14.86 - 15.25
52 Week Range
7.900 - 21.03
Volume
574,149
Market Cap
746.02M
PE Ratio (TTM)
26.46
EPS (TTM)
0.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
953,074
Chart
About Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with various debilitating conditions, particularly respiratory and gastrointestinal diseases. Their portfolio includes a range of novel products and drug candidates designed to improve patient outcomes by addressing unmet medical needs. The company places a strong emphasis on advancing its scientific research and collaborations to enhance treatment options and contribute to the overall health and well-being of patients around the world. Read More
A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Theravance Biopharma (TBPH) reported Q3 2025 results, beating EPS estimates with a profit of $0.04. Revenue was slightly below forecasts. Lead drug YUPELRI achieved record sales.
